This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Swisher-McClure S , Mitra N , Woo K , Smaldone M , Uzzo R , Bekelman JE
Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer
Int J Radiat Oncol Biol Phys. 2014 May 1;89(1) :103-12
PMID: 24725694 PMCID: PMC4049263
AbstractPURPOSE: To examine recent practice patterns, using a large national cancer registry, to understand the extent to which dose-escalated external beam radiation therapy (EBRT) has been incorporated into routine clinical practice for men with prostate cancer. METHODS AND MATERIALS: We conducted a retrospective observational cohort study using the National Cancer Data Base, a nationwide oncology outcomes database in the United States. We identified 98,755 men diagnosed with nonmetastatic prostate cancer between 2006 and 2011 who received definitive EBRT and classified patients into National Comprehensive Cancer Network (NCCN) risk groups. We defined dose-escalated EBRT as total prescribed dose of >/=75.6 Gy. Using multivariable logistic regression, we examined the association of patient, clinical, and demographic characteristics with the use of dose-escalated EBRT. RESULTS: Overall, 81.6% of men received dose-escalated EBRT during the study period. The use of dose-escalated EBRT did not vary substantially by NCCN risk group. Use of dose-escalated EBRT increased from 70.7% of patients receiving treatment in 2006 to 89.8% of patients receiving treatment in 2011. On multivariable analysis, year of diagnosis and use of intensity modulated radiation therapy were significantly associated with receipt of dose-escalated EBRT. CONCLUSIONS: Our study results indicate that dose-escalated EBRT has been widely adopted by radiation oncologists treating prostate cancer in the United States. The proportion of patients receiving dose-escalated EBRT increased nearly 20% between 2006 and 2011. We observed high utilization rates of dose-escalated EBRT within all disease risk groups. Adoption of intensity modulated radiation therapy was strongly associated with use of dose-escalated treatment.
NotesSwisher-McClure, Samuel Mitra, Nandita Woo, Kaitlin Smaldone, Marc Uzzo, Robert Bekelman, Justin E United States Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):103-12. doi: 10.1016/j.ijrobp.2014.01.050.